| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60fd476c1146f273e25b24a79bc702fc |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89f68f97fa351fac0f622b1957151efe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28bfdb5bc95b648f553a23b178ec58a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09330cc3c3f4664b309795aaed48d825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34e205b5b89817c39a160d6fc6fb2c80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b8cdd1588b3ac24a36f07f9420764d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2a59ba630c1d73c8c71b82272c1530f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5681353010ee3ecda0e0bc3e36ac3c0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2de832201146771f4cfb1ffb261d3c35 |
| publicationDate |
2017-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170123502-A |
| titleOfInvention |
Pharmaceutical composition for preventing or treating angiogenic diseases comprising collagen and pigemented epithelium derived factor |
| abstract |
The present invention relates to a pharmaceutical composition for preventing or treating a neovascular disease comprising collagen and pigment epithelial derived factor as an active ingredient. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating neovascular diseases comprising collagen type I and PEDF It is possible to increase the anti-angiogenic activity cycle and extend the dosage range of PEDF. Therefore, it is possible to solve the inconvenience due to the frequent injection of PEDF and the side effects thereof, and it can be applied to various angiogenic diseases therapeutic agents. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11197918-B2 |
| priorityDate |
2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |